drugset / Trial / NCT04567303
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Timeline
- Start
- 2020-10-28
- Primary completion
- 2026-08-25
- Completion
- 2026-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 100 mg/ml | Other |
| Subject | Zifibancimig | Monoclonal antibody | — | Intravitreal |